Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie’s Gonzalez Expects More PBM Deals To Come In HCV

This article was originally published in The Pink Sheet Daily

Executive Summary

The AbbVie CEO said his company and Gilead are just engaging in the normal market dynamics that occur when an entrenched product faces viable competition for the first time. Gilead’s formulary agreement for its HCV drugs with CVS quickly followed the rapid decision by Express Scripts to give preferred formulary status to AbbVie’s Viekira Pak.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel